Imfinzi is first and only immunotherapy to show survival benefit in ...
WEBJun 2, 2024 · Imfinzi is the only approved immunotherapy and the global standard of care in the curative-intent setting of unresectable, Stage III non-small cell lung cancer (NSCLC) in patients whose disease has not progressed after chemoradiation therapy.
IMFINZI® (durvalumab) perioperative regimen reduced the risk of ...
WEB5 days ago · WILMINGTON, Del., September 15, 2024--Positive results from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with chemotherapy demonstrated a statistically ...
Imfinzi Improves Survival in Small Cell Lung Cancer - NCI
WEBJun 25, 2024 · The immunotherapy drug durvalumab (Imfinzi) helped people with early-stage small cell lung cancer live longer, according to initial results from a large clinical trial. Durvalumab is a type of immunotherapy called an immune checkpoint inhibitor.
FDA approves neoadjuvant/adjuvant durvalumab for resectable …
WEBOn August 15, 2024, the FDA approved durvalumab (Imfinzi, AstraZeneca) with platinum-containing chemotherapy as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant...
Update on ADJUVANT BR.31 Phase III trial of Imfinzi in ... - AstraZeneca
WEBJun 25, 2024 · Imfinzi is the only approved immunotherapy and the global standard of care in the curative-intent setting of unresectable, Stage III NSCLC in patients whose disease has not progressed after chemoradiation therapy.
IMFINZI® (durvalumab) is the first and only immunotherapy to …
WEBJun 2, 2024 · IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo...
IMFINZI® (durvalumab) demonstrated statistically significant and ...
WEBJun 25, 2024 · IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase...
Imfinzi Continuously Demonstrates Survival Benefit in Limited …
WEB5 days ago · The 36-month OS rates were 62.1% versus 56.5%, respectively. Among patients who had no prior PCI in the Imfinzi (122 patients) and placebo arms (123 patients), data showed a median OS of 37.3 months and 24.1 months in each arm. After three years, the OS rates were 50.2% with Imfinzi versus 37.3% with placebo.
AZN : IMFINZI Regimen Reduces Death Risk By 25% In Late-Stage …
WEB5 days ago · An estimated 82.2% of patients treated with the IMFINZI regimen were alive at two years compared to 75.2% in the comparator arm. For More Such Health News, visit rttnews.com.
FDA expands approval of Imfinzi to reduce the risk of non-small …
WEBThe U.S. Food and Drug Administration today approved Imfinzi (durvalumab) for the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumors are not able to be...